Holen Sie sich die Stockscreener-App
6.535
2.61%
-0.175
Organon Co Aktie (OGN) Neueste Nachrichten
Aviance Capital Partners LLC Takes $599,000 Position in Organon & Co. $OGN - MarketBeat
Institutional Investors May Adopt Severe Steps After Organon & Co.'s (NYSE:OGN) Latest 26% Drop Adds to a Year Losses - 富途牛牛
Organon & Co. $OGN Holdings Cut by Fisher Funds Management LTD - MarketBeat
Organon & Co. Stock Plummets to New 52-Week Low of $6.18 - Markets Mojo
Co. (7XP) stock survive global slowdownQuarterly Risk Review & Real-Time Chart Pattern Alerts - newser.com
Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN) - MSN
KLCM Advisors Inc. Decreases Stake in Organon & Co. $OGN - MarketBeat
Crisis at Organon: Leadership Ousted Amid Sales Scandal - AD HOC NEWS
Tangible book value per share of Organon & Co. – BMV:OGN - TradingView
Organon & Co. (OGN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
OGN 8-K/A discloses interim Executive Chair compensation terms - Stock Titan
The Vanguard Group files 13G/A for Organon with 13.82% stake - Stock Titan
Organon & Co. Common Stock (NY: OGN - FinancialContent
The Escalator: Organon, Kenvue, Real Chemistry and more - Medical Marketing and Media
Organon & Co. $OGN Shares Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Co. (7XP) stock in 20252025 Sector Review & Safe Entry Point Alerts - newser.com
Organon & Co. (OGN) Stock forecasts - Yahoo! Finance UK
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon (OGN) Price Target Decreased by 15.36% to 11.05 - Nasdaq
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Organon: Critical Assessment Of The Audit Committee Investigation Results (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Down 6.2% Following Analyst Downgrade - MarketBeat
Organon Looks For New CEO Amid Investigation Into Front-Loading Contraceptive Implant Sales - Citeline News & Insights
Organon (OGN) Is Down 26.2% After CEO Resignation and Audit Reveals Sales Practice Issues – What's Changed - simplywall.st
Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN - MarketBeat
D.A. Davidson & CO. Sells 50,248 Shares of Organon & Co. $OGN - MarketBeat
Why Organon (OGN) Stock Is Down Today - Yahoo Finance
Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade
Organon hit hard over ousted CEO scandal - The Pharma Letter
The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Hits New 52-Week Low After Analyst Downgrade - MarketBeat
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - MarketScreener
Organon & Co. (NYSE:OGN) Downgraded by Piper Sandler to Underweight - MarketBeat
Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛
Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize
Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Australia
Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ
Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada
Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - MSN
Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma
Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize
Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ
Organon CEO exits after internal probe over ‘channel stuffing’ to boost sales - Endpoints News
Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance
Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's
Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target - MarketScreener
Organon Appoints Interim CEO and Board Chair; Reports Results of Audit Committee Investigation - New Jersey Business Magazine
Piper Sandler Downgrades Organon & Co(OGN.US) to Sell Rating, Cuts Target Price to $5 - 富途牛牛
Organon cut to Underweight at Piper Sandler on internal control concerns - Seeking Alpha
Organon Appoints Company Executive Joseph Morrissey as Interim CEO - citybiz
Organon & Co stock hits 52-week low at 7.26 USD By Investing.com - Investing.com South Africa
Organon CEO Resigns After Probe Finds Improper Sales Practices - Bloomberg
Organon Shares, Bonds Tumble Amid Improper Sales Findings (1) - Bloomberg Law News
Organon appoints company executive Joseph Morrissey as interim CEO and board chair Carrie Cox as executive chair; announces results of audit committee investigation - MarketScreener
1.28%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):